Home blood pressure (BP) monitoring may enhance assessment of BP control. In this 16-week study, men and women 70 years or older with systolic BP between 150 and 200 mm Hg were randomized to receive valsartan/hydrochlorothiazide (V/HCTZ) 160/12.5 mg (n = 128), HCTZ 12.5 mg (n = 128), or V 160 mg (n = 128) for 4 weeks. Participants whose BP was 140/90 mm Hg or higher at weeks 4, 8, or 12 were uptitrated to a maximum of V/HCTZ 320/25 mg. Participants were evaluated by home BP monitoring using an automated device weekly before taking daily study medication (n = 301). Baseline BP ± SD for clinic (165.5 ± 11.8/85.1 ± 9.5 mm Hg) was approximately 3/1 mm Hg greater than home readings (162.5 ± 15.8/84.3 ± 10.2 mm Hg). Reductions in BP ± SEM at week 4 were similar for clinic (12.6 ± 1.0/4.7 ± 0.5 mm Hg) and home (10.9 ± 1.1/3.8 ± 0.5 mm Hg) readings (P = .25/P = .23; clinic versus home); differences between V/HCTZ and HCTZ or V were also similar for both home and clinic readings and results by either technique correlated significantly (P < .0001). Home BP measurements confirm that treatment initiated with V/HCTZ versus monotherapy resulted in greater antihypertensive efficacy. Home BP monitoring, if done with proper technique, provides a reliable indicator of BP control in elderly patients and may help guide drug dosing and titration.
Bibliographical noteFunding Information:
Funding/support: This study was funded by Novartis Pharmaceuticals Corporation , East Hanover, New Jersey, USA. Editorial assistance from Oxford PharmaGenesis was funded by Novartis Pharmaceuticals Corporation . The authors express their appreciation to Colleen Faller of Novartis Pharmaceuticals Corporation for expert assistance in project management ( ClinicalTrials.gov identifier: NCT00698646 ).
Conflict of interest: W.C.C.: Consultancies at Takeda, Merck, Daiichi-Sankyo, Omron; grant support from Merck; stock ownership/financial interests: none. D.A.D.: Speakers’ Bureau at Novartis Pharmaceuticals Corporation, Forest, Pfizer, Merck; advisory boards at Novartis Pharmaceuticals Corporation, Pfizer, Abbott; grant support from Novartis Pharmaceuticals Corporation, Roche; stock ownership/financial interests: none. H.S.W.: consultancies at Gilead; Speakers’ Bureau at Novartis Pharmaceuticals Corporation, Daiichi-Sankyo, Takeda, AstraZeneca, Gilead, Abbott, Kowa; grant support: none; stock ownership/financial interests: none. D.P., D.Z., and R.S. are employees of Novartis Pharmaceuticals Corporation. J.L.I.: Consultancies at Boehringer-Ingelheim, Forest Laboratories, Novartis Pharmaceuticals Corporation, Daiichi-Sankyo, Takeda; grant support from GlaxoSmithKline, Novartis Pharmaceuticals Corporation; stock ownership/financial interests: none.
Copyright 2013 Elsevier B.V., All rights reserved.
- blood pressures monitoring technique
- randomized controlled trial